Introduction
============

The clinical course of probable dementia with Lewy bodies (DLBs) is influenced by the amount of concomitant Alzheimer's neurofibrillary tangle (NFT) pathology, subtype of Lewy body disease (LBD), transitional versus diffuse and burden of α-synuclein pathology ([@fcaa040-B10]; [@fcaa040-B17]; [@fcaa040-B7]). DLB patients have a more aggressive clinical course than Alzheimer's patients, with a shorter survival from disease onset, faster cognitive decline and shorter disease duration before nursing-home admission ([@fcaa040-B25]; [@fcaa040-B30]; [@fcaa040-B27]). Therefore, antemortem biomarkers of neuropathology may allow for more accurate prognosis. For example, smaller hippocampal volumes as an indirect surrogate of Alzheimer's disease pathology have been associated with shorter survival among DLB patients ([@fcaa040-B12]). DLB patients with a CSF profile suggestive of coexisting Alzheimer's disease pathology are more likely to be admitted to a nursing home and have shorter disease duration than DLB patients without evidence of coexisting Alzheimer's disease pathology in CSF.

Using ^18^F-fluorodeoxyglucose (^18^F-FDG) PET, occipital hypometabolism and a higher cingulate island sign (CIS) ratio distinguish patients with DLB from Alzheimer's disease dementia ([@fcaa040-B21]; [@fcaa040-B18]). The objectives of this study were to (i) determine whether these FDG PET signatures of DLB are associated with pathology in autopsy-confirmed DLB and (ii) to determine whether PET features associate with clinical course in clinically probable DLB.

Materials and methods
=====================

Participants
------------

For this study we included two participant groups. The first group were participants with pathologically confirmed LBD who underwent antemortem FDG PET (*n* = 34). For this analysis, the FDG-PET closest to death was used. The second group (*n* = 87) included consecutive participants from the Mayo Clinic Alzheimer's Disease Research Center with a clinical diagnosis of probable DLB ([@fcaa040-B22]) who underwent ^18^F-FDG (*n* = 87). A subset of this group was included in the autopsy-confirmed group. For this analysis, the baseline FDG-PET was used.

As part of the Alzheimer's Disease Research Center evaluation, participants routinely undergo neurological examination and neuropsychological testing. The Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) was used to assess the clinical disease severity of these participants ([@fcaa040-B3]; [@fcaa040-B24]).

DLB clinical features
---------------------

Participants met consensus criteria for probable DLB ([@fcaa040-B22]). Clinical DLB features included the following: (i) visual hallucinations were fully formed, occurred more than once and were not attributable to other medical factors; (ii) Parkinsonism severity was assessed using the Unified Parkinson's Disease Rating Scale, and the presence of parkinsonism was judged to be present or absent by the examining neurologist; (iii) diagnosis of probable rapid eye movement sleep behaviour disorder or REM behaviour disorder was based on a history of recurrent, apparent dream-enactment behaviour ([@fcaa040-B4]); and (iv) a score of 3 or 4 on the Mayo Fluctuations Questionnaire, which is necessary for fluctuations to be considered present ([@fcaa040-B1]; [@fcaa040-B8]).

MRI and FDG-PET acquisitions
----------------------------

MRI examinations were performed at 3-T with an eight-channel phased array coil (GE Healthcare; Waukesha, WI, USA). A three-dimensional high-resolution magnetization-prepared rapid-acquisition gradient echo acquisition with repetition time/echo time/inversion time of 7/3/900 ms, a flip angle of 8° and 1.2 mm (R/L) × 1.0 mm (A/P) × 1.0 mm (S/I) resolution was performed for anatomical segmentation and labelling. PET images were obtained with a LYSO PET/CT scanner (DRX; GE Healthcare) functioning in three-dimensional mode. Attenuation correction was achieved by obtaining a CT image. Patients received FDG \[average (range), 540 (366--399) MBq\] injections. An 8-min FDG scan was obtained, after a 30-min FDG uptake period. Image acquisition included four 2-min dynamic frames, acquired from 30 to 38 min after injection. FDG-PET image volumes of each patient were co-registered to the patient's own T~1~-weighted MRI scan ([@fcaa040-B29]). ANTs software ([@fcaa040-B2]) was employed to compute a deformation from the Mayo Clinic Adult Lifespan Template ([@fcaa040-B28]) to each subject's native MRI space, and the resulting deformation was applied to an in-house modified version of the automated anatomical labelling atlas ([@fcaa040-B29]). Using the resulting subject-specific atlas, FDG-PET uptake values were extracted from each cortical region of interest. Pons was used as an internal reference region of interest for FDG PET normalization to calculate FDG PET scaled uptake value ratio images. The median value in each target cortical (occipital lobe) region of interest was divided by the median value in the pontine region of interest for FDG PET images. The FDG CIS ratio was defined as posterior cingulate divided by the sum of the precuneus plus cuneus FDG uptake ratio ([@fcaa040-B28]).

Neuropathology
--------------

Sampling was done according to the Consortium to Establish a Registry for Alzheimer's Disease protocol ([@fcaa040-B23]). Braak NFT stage ([@fcaa040-B5]) and neuritic plaques were interpreted using AT8 immunostaining (1:1000; Endogen, Woburn, MA, USA), thioflavin-S microscopy and a modified Bielschowsky silver stain. Alzheimer's disease was diagnosed using NIA-Alzheimer Association recommendations ([@fcaa040-B14]). A monoclonal antibody to α-synuclein (LB509) was used to assess distribution of Lewy body pathology, and LBD cases were classified as brainstem, transitional or diffuse, according to criteria of Fourth Consensus Report of the DLB Consortium ([@fcaa040-B22]). Neuropathologists were blinded to the FDG PET results. The analysis in this report focused on Braak NFT stage and Lewy body subtype. Transitional LBD included participants with Lewy-body pathology in brainstem and limbic regions, while diffuse LBD included those with Lewy-related pathology in the neocortex in addition to the brainstem and limbic regions.

Statistical analysis
--------------------

Demographic and clinical characteristics of the participants were summarized using means and standard deviations for numerical variables and counts and percentages for categorical variables.

We conducted statistical analyses to answer three broad questions in a stepwise fashion:

i.  'Are the FDG PET signatures of DLB patients associated with LBD subtype or Braak NFT stage?'

    First, we determined whether the CIS ratio or occipital hypometabolism differed between those with transitional LBD versus diffuse LBD or by Braak NFT stage. We compared the LBD groups using *t*-tests for numerical variables and chi-squared tests for differences in proportions. For the Braak NFT staging analysis, comparisons were done with ANOVA and chi-squared testing. We did not find an association with occipital hypometabolism, so it was excluded from further analyses.

ii. 'Can we develop data-driven cut-points for the CIS ratio using Braak NFT stage?'

    Since the FDG CIS ratio was associated with Braak NFT stage, we wanted to divide the data into subgroups using cut-points. We performed a recursive-partitioning tree algorithm on Braak NFT stage to classify our participants into CIS subgroups.

iii. 'Can the CIS ratio predict the clinical severity and projected course of participants clinically diagnosed with probable DLB?'

Associations between clinical course and CIS ratio
--------------------------------------------------

We first ran regression models using age at MRI, education, duration of disease and CIS ratio to predict cognition as measured with CDR-SB and mini-mental state examination (MMSE) in 87 participants with baseline PET. CDR-SB was log-transformed to meet regression assumptions. After fitting the full model, we formed a parsimonious model using backwards elimination. The parsimonious model reduced to a simple linear regression of the CIS ratio on the log of CDR-SB. We repeated this approach with MMSE as an outcome. MMSE was transformed by squaring the values to meet regression assumptions. The parsimonious model was again a simple linear regression with CDR-SB as the predictor. We then ran mixed models using CDR-SB to investigate longitudinal associations in individuals with data from at least two time points (*n* = 51, 143 records). The mixed models used time from baseline, baseline age at MRI, education, duration of disease and FDG CIS ratio to predict longitudinal cognition (CDR-SB). CDR-SB was again log-transformed to meet regression assumptions. A parsimonious model was formed using backwards elimination. We included random subject-specific intercepts and slopes (a likelihood ratio test indicated that the slopes were necessary, *P* \< 0.001). We did not run longitudinal models for MMSE due to the smaller available sample size (37 individuals with missing values).

This study was approved by the Mayo Clinic Institutional Review Board, and informed consent for participation was obtained from every participant and/or an appropriate surrogate.

Data availability
-----------------

Data from the Mayo Clinic Study of Aging, including data from this study, are available upon request.

Results
=======

Pathology cohort
----------------

The characteristics of participants with FDG PET and LBD pathology are summarized in [Table 1](#fcaa040-T1){ref-type="table"} by LBD subtype and Braak NFT stage. Three distinct groups ([Fig. 1](#fcaa040-F1){ref-type="fig"}) based on the partitioning analysis---low Braak NFT stage (I--II), medium Braak NFT stage (III--IV) and high Braak NFT stage (V--VI) were identified. The mean FDG CIS ratio was 0.98 for the high Braak group, 1.07 for the medium Braak group and 1.15 for the low Braak group; with a box plot showing the individual observations ([Fig. 2](#fcaa040-F2){ref-type="fig"}).

![**CIS ratio subgroups by Braak NFT stage with recursive partitioning**.](fcaa040f1){#fcaa040-F1}

![**Box plots of CIS ratio by Braak neurofibrillary tangle stage**.](fcaa040f2){#fcaa040-F2}

###### 

Characteristics by LBD subtype and Braak NFT stage

                                           LBD subtype   Braak NFT group                                                     
  ---------------------------------------- ------------- ----------------- ------- ------------- ------------- ------------- -------
  *N*                                      26            8                         10            17            7             
  Age (years), mean (SD)                   72.7 (6.2)    74.6 (9.3)        0.49    72.0 (6.9)    74.3 (7.2)    71.9 (6.9)    0.63
  Male, *n* (%)                            18 (69)       7 (88)            0.31    10 (100)      12 (71)       3 (43)        0.029
  APOE ϵ4 allele, *n* (%)                  17 (65.4)     3 (37.5)          0.16    5 (50.0)      8 (47.1)      7 (100.0)     0.045
  Years from imaging to death, mean (SD)   2.7 (1.5)     2.1 (1.4)         0.36    2.5 (1.1)     2.3 (1.4)     3.1 (2.0)     0.43
  MMSE, mean (SD)                          17.3 (6.8)    22.4 (4.4)        0.06    21.3 (5.4)    17.9 (6.3)    16.1 (8.3)    0.26
  CDR sum of boxes, mean (SD)              8.3 (4.7)     4.5 (2.2)         0.036   5.0 (3.1)     8.6 (4.7)     8.0 (5.0)     0.12
  FDG CIS ratio, mean (SD)                 1.07 (0.12)   1.11 (0.09)       0.42    1.15 (0.12)   1.07 (0.07)   0.98 (0.13)   0.008
  FDG occipital, SUVR, mean (SD)           1.27 (0.19)   1.34 (0.16)       0.38    1.27 (0.19)   1.28 (0.21)   1.33 (0.10)   0.78
  Vis. hallucinations, *n* (%)             16 (67)       4 (67)            1.00    6 (67)        11 (73)       3 (50)        0.59
  Fluctuations, *n* (%)                    17 (71)       4 (67)            0.84    7 (78)        11 (73)       3 (50)        0.48
  Parkinsonism, *n* (%)                    17 (71)       6 (100)           0.13    9 (100)       12 (80)       2 (33)        0.010
  Probable RBD, *n* (%)                    19 (79)       6 (100)           0.22    9 (100)       13 (87)       3 (50)        0.035

CIS = cingulate island sign; DLBD = diffuse Lewy body disease; SD = standard deviation; SUVR = standardized uptake value ratio; TLBD = transitional Lewy body disease.

Clinical cohort
---------------

The characteristics of participants in the clinical cohort at the time of baseline FDG PET scan are reported in [Table 2](#fcaa040-T2){ref-type="table"}. A linear regression model using age at MRI, education, duration of disease and CIS was used to predict cognition (CDR-SB) and reported in [Table 3](#fcaa040-T3){ref-type="table"}. We found that the CIS ratio was (inversely) associated with CDR-SB (coefficient ± standard error) −2.31 ± 0.65, *P* = 0.001. CIS was the single predictor associated with CDR-SB in the parsimonious model after removing non-significant adjustment variables (−2.40 ± 0.61, *P* \< 0.001).

###### 

Demographics of probable DLB participants with baseline FDG PET

                                   Clinical cross-sectional (*n* = 87)   Clinical longitudinal (*n* = 51)^a^
  -------------------------------- ------------------------------------- -------------------------------------
  Age (years), mean (SD)           70.2 (8.0)                            70.0 (7.6)
  Male, *n* (%)                    74 (85)                               44 (86)
  APOE ϵ4 allele, *n* (%)          36 (46.8)                             23 (45.1)
  MMSE, mean (SD)                  21.2 (6.7)                            22.2 (6.3)
  CDR sum of boxes, mean (SD)      5.5 (3.4)                             4.8 (2.8)
  FDG CIS, mean (SD)               1.11 (0.10)                           1.12 (0.10)
  Visual hallucinations, *n* (%)   52 (59.8)                             30 (58.8)
  Fluctuations, *n* (%)            61 (70.1)                             40 (78.4)
  Parkinsonism, *n* (%)            79 (90.8)                             47 (92.2)
  Probable RBD, *n* (%)            76 (87.4)                             46 (90.2)

The clinical longitudinal group is a subset of the cross-sectional group.

RBD = rapid eye movement sleep behaviour disorder.

###### 

Linear regression model predicting CDR-sum of boxes

  Predictor                             Coefficient (standard error)   *P*-value
  ------------------------------------- ------------------------------ -----------
  Full model (*R*^2^ = 0.208)                                          
   Intercept                            3.21 (1.02)                    0.002
   Age                                  0.002 (0.008)                  0.777
   Education                            0.042 (0.021)                  0.047
   Duration of disease                  0.001 (0.001)                  0.516
   CIS                                  −2.31 (0.65)                   0.001
  Parsimonious model (*R*^2^ = 0.154)                                  
   Intercept                            4.19 (0.68)                    \<0.001
   CIS                                  −2.40 (0.61)                   \<0.001

The association between FDG CIS ratio and CDR-SB (line from the parsimonious model) is visualized in [Fig. 3](#fcaa040-F3){ref-type="fig"}. The estimated mean CDR-SB was generally lower (i.e. less impaired) with increasing FDG CIS ratio. We used the FDG CIS ratios derived from the autopsy cohort (mean FDG).

![**The association between FDG CIS ratio and CDR sum of boxes**.](fcaa040f3){#fcaa040-F3}

CIS ratios were 0.98 for the high Braak NFT stage group, 1.07 for the medium Braak NFT stage group and 1.15 for the low Braak NFT stage group to illustrate predicted CDR-SB values at these three important points. The models using MMSE as an outcome showed similar results, with lower FDG CIS ratio associated with greater clinical impairment as measured by MMSE (results not shown).

Longitudinal results
--------------------

Next, we constructed mixed models on the subset of individuals with at least two time points, using baseline age at MRI, education, duration of disease and CIS ratio to predict longitudinal cognition (CDR-SB) in 51 participants with longitudinal visits (143 observations). CDR-SB was again log transformed to meet regression assumptions. The full and parsimonious models are reported in [Table 4](#fcaa040-T4){ref-type="table"}. The baseline FDG CIS ratio was associated with log of CDR-SB. There was an interaction between time and disease duration on log CDR-SB indicating the effect of time was less the longer the patient was symptomatic (early in the disease CDR-SB changes more). Using the parsimonious mixed model, predicted values for median education (15 years) and median duration of disease (67 months) were generated. Predicted CDR-SB scores for low values of the FDG CIS ratio (relatively lower posterior cingulate metabolism) start higher (i.e. more impaired) and increase faster than for high values of the FDG CIS ratio. In order to illustrate the possible relationship with pathology, we show predicted values on the plots from the results of the recursive partitioning using the same mean values as before ([Fig. 4](#fcaa040-F4){ref-type="fig"}).

![**Longitudinal predicted CDR-SB at different CIS ratios reflecting different Braak NFT stages; 'dark blue'---FDG CIS at minimum; 'brown'---mean FDG CIS, high Braak; 'light blue'---mean FDG CIS, medium Braak; black---mean FDG CIS, low Braak; 'violet'---FDG CIS at maximum**.](fcaa040f4){#fcaa040-F4}

###### 

Mixed model to predict longitudinal CDR-sum of boxes

  Predictor                                                    Coefficient (standard error)   *P*-value
  ------------------------------------------------------------ ------------------------------ -----------
  Full model                                                                                  
   Intercept                                                   1.59 (1.09)                    0.147
   Time                                                        0.14 (0.48)                    0.779
   Age                                                         0.004 (0.008)                  0.618
   Education                                                   0.07 (0.02)                    0.001
   Duration of disease                                         0.002 (0.001)                  0.131
   CIS                                                         −1.57 (0.67)                   0.023
   Time[\*](#tblfn4){ref-type="table-fn"}age                   0.003 (0.004)                  0.519
   Time[\*](#tblfn4){ref-type="table-fn"}education             −0.02 (0.01)                   0.092
   Time[\*](#tblfn4){ref-type="table-fn"}duration of disease   −0.001 (0.001)                 0.053
   Time[\*](#tblfn4){ref-type="table-fn"}CIS                   0.261 (0.335)                  0.437
  Parsimonious model                                                                          
   Intercept                                                   1.93 (0.86)                    0.027
   Time                                                        0.34 (0.05)                    \<0.001
   Education                                                   0.07 (0.02)                    0.001
   Duration of disease                                         0.002 (0.001)                  0.127
   CIS                                                         −1.55 (0.64)                   0.020
   Time[\*](#tblfn4){ref-type="table-fn"}duration of disease   −0.001 (0.001)                 0.045

Indicates interaction.

Discussion
==========

The main findings of this study are the following. First, among patients with LBD pathology who underwent antemortem FDG PET, the FDG CIS ratio correlated with Braak NFT stage but not with LBD subtype (transitional LBD versus diffuse LBD). Occipital metabolism was not associated with either Braak NFT stage or LBD subtype. Second, in participants with probable DLB, the FDG CIS ratio was associated with cognition at baseline and longitudinally.

Several studies have highlighted the usefulness of the CIS in distinguishing Alzheimer's dementia from DLB ([@fcaa040-B21]; [@fcaa040-B13]; [@fcaa040-B16]), but the pathological associations of the CIS have not been clearly delineated. In an earlier study of eight DLB patients, we showed a relationship between higher CIS and lower Braak NFT stage, but only six of these patients had LBD, so confirmation in a larger autopsy series was necessary ([@fcaa040-B13]). In contrast, no association with neurodegenerative pathology was found using single-photon emission computed tomography with ^99m^Tc-hexamethylpropyleneamine oxime in 12 DLB patients ([@fcaa040-B26]). However, this imaging technique is known to have lower sensitivity than FDG PET and is a measure of blood flow, not metabolism. In the current larger study, we found a strong relationship between higher (worse) Braak NFT stage and lower (worse) CIS ratio. Similarly, a higher CIS has been associated with less hippocampal atrophy, providing indirect evidence of its association with Alzheimer's disease NFT pathology ([@fcaa040-B15]). The key finding in our study is that CIS FDG ratios are significantly associated with Braak stage in the DLB spectrum. Additionally, the baseline CIS ratio appears to be a promising biomarker of longitudinal cognitive trajectory in DLB.

Understanding the clinical DLB spectrum requires an appreciation of both Lewy bodies and Alzheimer's disease neuropathology. The majority of patients with DLB who come to autopsy have co-existing Alzheimer's disease pathology ([@fcaa040-B9]). In a large clinical sample of DLB patients who underwent CSF examination for Alzheimer's disease biomarkers, nearly 40% had biomarker evidence of co-existing Alzheimer's disease ([@fcaa040-B20]). The presence of Alzheimer's disease pathology influences the phenotype and clinical course of LBD patients. For example, burden of NFT was associated with a shorter survival ([@fcaa040-B17]) and worse cognitive performance in autopsied LBD patients ([@fcaa040-B6]). Similarly, in patients with a clinical DLB diagnosis, the presence of CSF evidence of co-existing Alzheimer's disease has been associated with a worse cognitive performance and higher risk of nursing home admission ([@fcaa040-B20]). Additionally, DLB patients without hippocampal atrophy on MRI or evidence of amyloid deposition on PET are more likely to respond to acetylcholinesterase inhibitors ([@fcaa040-B11]). Therefore, our findings that the CIS ratio predicts clinical progression align with findings from both pathology and biomarker studies.

We did not find a pathological correlate of occipital hypometabolism. It is possible that if we compared Alzheimer's disease dementia cases with DLB cases we would have found a difference, since occipital hypometabolism also distinguishes Alzheimer's disease from DLB ([@fcaa040-B18]).

While the CIS was associated with Braak NFT stage, we did not see a difference in the CIS ratio between transitional and diffuse LBD. Pathological studies have suggested that those with diffuse LBD have a worse prognosis than those with transitional LBD, and when quantified, α-synuclein burden also predicts a worse prognosis ([@fcaa040-B10]; [@fcaa040-B7]). As both of our FDG measures failed to predict LBD subtype, developing α-synuclein biomarkers is needed to improve the diagnostic capabilities for LB pathology.

Future studies will determine whether direct measures of Alzheimer's disease neuropathology by PET (amyloid and tau) or in the CSF predict the clinical course better than FDG PET. Since a high proportion of DLB patients have concomitant Alzheimer's disease neuropathology, FDG PET may complement the information provided by Alzheimer's disease biomarkers as a diagnostic and prognostic biomarker.

Conclusions
===========

Among pathologically confirmed LBD patients, FDG-PET features varied by Braak NFT stage, but not the LBD subtype. Prior pathology studies and biomarker studies demonstrate that the extent of coexisting NFT pathology of Alzheimer's disease predicts a worse prognosis. The CIS ratio is associated with CDR-SB and MMSE and predicts clinical trajectory in DLB.
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